Website
News25/Ratings8
News · 26 weeks37-90%
2025-10-262026-04-19
Mix2790d
- Insider11(41%)
- SEC Filings7(26%)
- Earnings3(11%)
- Other2(7%)
- Leadership2(7%)
- M&A1(4%)
- Other1(4%)
Latest news
25 items- PRTactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that first quarter of fiscal year 2026 financial results will be released after the market closes on Monday, May 4, 2026. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on May 4, 2026, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13759535. A live webcast of the call will also be provided on the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Tactile Systems Technology Inc.SCHEDULE 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
- SECSEC Form DEFA14A filed by Tactile Systems Technology Inc.DEFA14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- SECSEC Form DEF 14A filed by Tactile Systems Technology Inc.DEF 14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- PRNeuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsTotal revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; proven medical device leader with more than 30 years of experience scaling commercial healthcare businesses MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM
- PRNeuronetics Appoints Dan Reuvers as President and Chief Executive OfficerMALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin
- INSIDERSEC Form 3 filed by Tactile Systems Technology Inc.3 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERDirector Pearson Andrea was granted 852 shares (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- SECSEC Form PRE 14A filed by Tactile Systems Technology Inc.PRE 14A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- SECTactile Systems Technology Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- PRTactile Medical Strengthens Board of Directors with Appointment of Andrea PearsonMINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Andrea Pearson to the Company's Board of Directors ("Board") and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, market
- INSIDERChief Executive Officer Dodd Sheri Louise sold $318,144 worth of shares (10,993 units at $28.94), decreasing direct ownership by 4% to 243,885 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Birkemeyer Elaine M. sold $222,880 worth of shares (7,701 units at $28.94), decreasing direct ownership by 5% to 134,819 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERSr. VP Mktg & Clinical Affairs Burns Kristie sold $180,764 worth of shares (6,246 units at $28.94), decreasing direct ownership by 7% to 82,581 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Birkemeyer Elaine M. was granted 25,919 shares and sold $156,144 worth of shares (5,518 units at $28.30), increasing direct ownership by 17% to 142,520 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERChief Executive Officer Dodd Sheri Louise sold $431,245 worth of shares (15,240 units at $28.30) and was granted 47,967 shares, increasing direct ownership by 15% to 254,878 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERSr. VP Mktg & Clinical Affairs Burns Kristie sold $125,612 worth of shares (4,439 units at $28.30) and was granted 14,671 shares, increasing direct ownership by 13% to 88,827 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- SECSEC Form 144 filed by Tactile Systems Technology Inc.144 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
- INSIDERChief Executive Officer Dodd Sheri Louise was granted 48,672 shares, increasing direct ownership by 28% to 222,151 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERSr. VP Mktg & Clinical Affairs Burns Kristie was granted 6,194 shares, increasing direct ownership by 9% to 78,595 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Birkemeyer Elaine M. was granted 23,008 shares, increasing direct ownership by 23% to 122,119 units (SEC Form 4)4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
- SECSEC Form 10-K filed by Tactile Systems Technology Inc.10-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- PRTactile Systems Technology, Inc. Reports Fourth Quarter and Full Year 2025 Financial ResultsMINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Summary: Total revenue increased 21% year-over-year to $103.6 millionGross margin of 78% versus 75% in Q4 2024Net income of $10.6 million versus $9.7 million in Q4 2024Adjusted EBITDA of $22.9 million versus $16.2 million in Q4 2024 Full Year 2025 Summary: Total revenue increased 12% year-over-year to $329.5 millionGross margin of 76%, compared to 74% in 2024Oper
- SECTactile Systems Technology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
- PRTactile Medical Acquires LymphaTech, Expanding Breadth and Depth of its Lymphedema Solutions PortfolioMINNEAPOLIS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that it has acquired LymphaTech Inc., for an upfront cash payment at closing of $6.8 million, plus potential additional consideration that is contingent upon the achievement of future milestones. Founded in 2014, LymphaTech, Inc. is a privately held medical technology company pioneering a digital, three-dimensional ("3D") full body measurement and monitoring platform designed specifically for lymphedema. Damage to the lymphatic system from chronic fluid accumulat